Literatur
-
1
Werbeanzeige der Firma Bayer AG für Acarbose.
Der Internist.
2003;
44
713
-
2 The STOP-NIDDM trial. Powerpoint-Folienvortrag. http://www.stop-niddm.com/study/slides.htm. Zugriff: 1. August 2003; teilweise jetzt verfügbar unter http://www.di-em.de
-
3
Chiasson J L. et al .
Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: Facts and interpretations concerning the critical analysis of The STOP-NIDDM Trial data.
Diabetologia.
2004;
47
(im Druck)
-
4
Hanefeld M. et al .
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
Eur Heart J.
2004;
25
10-16
-
5
Kaiser T, Sawicki P T.
Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.
Diabetologia.
2004;
47
575-580
Thomas Kaiser
DIeM - Institut für evidenzbasierte Medizin
Venloer Straße 301-303
50823 Köln
Phone: 0221/86967313
Fax: 0221/86967319
Email: t.kaiser@di-em.de
URL: http://www.di-em.de
